Mucosal-associated invariant T (MAIT) cells are activated by microbial riboflavin-based metabolite antigens when presented by MR1. How modifications to the potent antigen 5-OP-RU affect presentation by MR1 and MAIT cell activation remains unclear. Here we design 20 derivatives, termed altered metabolite ligands (AMLs), to dissect the impact of different antigen components on the human MAIT-MR1 axis. Analysis of 11 crystal structures of MAIT T cell antigen receptor (TCR)-MR1-AML ternary complexes, along with biochemical and functional assays, shows that MR1 cell-surface upregulation is influenced by ribityl and non-ribityl components of the ligand and the hydrophobicity of the MR1-AML interface. The polar ribityl chain of the AML strongly influences MAIT cell activation potency through dynamic compensatory interactions within a MAIT TCR-MR1-AML interaction triad. We define the basis by which the MAIT TCR can differentially recognize AMLs, thereby providing insight into MAIT cell antigen specificity and potency.
5-(2-Oxopropylideneamino)-6-d-ribitylaminouracil (5-OP-RU) is an atural productf ormedd uring bacterial synthesis of vitamin B2. It potently activates mucosal associated invariant T( MAIT) cells and has immunomodulatory,i nflammatory,a nd anticancer properties. This highly polar and unstable compound forms ar emarkablys table Schiff base with al ysine residuei nm ajor histocompatibility complex class Irelated protein (MR1) expressed in antigen-presentingc ells. Inspiredb yt he importance of the ribityl moiety of 5-OP-RU for binding to both MR1 and the Tc ell receptor (TCR) on MAIT cells, each OH was removed in silico. DFT calculations and MD simulations revealedavery stable hydrogen bond betweent he C3'ÀOH and uracil N1H, which profoundly restrictsf lexibility and positioning of each ribityl-OH, potentially impacting their interactionsw ith MR1 and TCR. By using deoxygenation strategies and kinetically controlled imine formation,f our monodeoxyribityl and four monohydroxyalkyl analogues of 5-OP-RU were synthesised as new tools for probingTcell activation mechanisms.[a] G.Scheme4.Synthesis of 4-deoxy-d-ribitylamine (32)b yB arton-McCombied eoxygenation of d-ribose (24).Scheme5.Synthesis of 5-deoxy-d-ribitylamine (40)b yC 5-tosylate reduction of d-ribose (24).
1-Azasugar analogues of l-iduronic acid (l-IdoA) and d-glucuronic acid (d-GlcA) and their corresponding enantiomers have been synthesized as potential pharmacological chaperones for mucopolysaccharidosis I (MPS I), a lysosomal storage disease caused by mutations in the gene encoding α-iduronidase (IDUA). The compounds were efficiently synthesized in nine or ten steps from d-or l-arabinose, and the structures were confirmed by X-ray crystallographic analysis of key intermedi-ates. All compounds were inactive against IDUA, although l-IdoA-configured 8 moderately inhibited β-glucuronidase (β-GLU). The d-GlcA-configured 9 was a potent inhibitor of β-GLU and a moderate inhibitor of the endo-β-glucuronidase heparanase. Co-crystallization of 9 with heparanase revealed that the endocyclic nitrogen of 9 forms close interactions with both the catalytic acid and catalytic nucleophile.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.